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LETTERS TO THE EDITOR 2305although to a greatly reduced extent compared with WT
Bmem cells (see Fig E6, A-C, in this article’s Online Repository
at www.jacionline.org). Consistent with this, the few Bmem cells
present in STK4-deficient patients were capable of differentiating
into ASCs in vitro, although at reduced levels (see Fig E6, D).
Interestingly, despite the impaired specific antibody secretion in
mice with Stk4Y88del/Y88del B cells, STK4 deficiency did not
quantitatively affect the ability of these SWHEL B cells to generate
plasma cells in vivo (Fig 2, I-K). Thus, similar to B cells from
STK4-deficient patients, Stk4Y88del/Y88del B cells are able to
differentiate into plasma cells, but these plasma cells do not
secrete adequate amounts of specific antibody.
STK4 is a multifunctional kinase that phosphorylates multiple
cellular proteins, including those in the Hippo signaling
pathway.E8,E9 Many of these substrates are also phosphorylated
by its paralog, STK3, suggesting STK3 might functionally
compensate for STK4 deficiency. Indeed, B-cell defects are
more readily observed in Stk3/Stk4 double-knockout mice.E5
Interestingly, STK4 has been shown to phosphorylate FOXO1
and promote its nuclear localization,E10 and FOXO1 was recently
shown to be required for dark zone formation and GCmaintenan-
ce.E11-E13 However, although FOXO1 levels were decreased in
Stk4Y88del/Y88del and Stk42/2 GC B cells, we could not rescue
the GC defect through retroviral overexpression of Foxo1 (see
Fig E7 in this article’s Online Repository at www.jacionline.
org), suggesting that other mechanisms might also be involved.
Another limitation of our study is the small number of patients
involved, which prevents any firm conclusion, especially
regarding differences in serum immunoglobulin levels in our
cohort of 9 patients and the previously reported 14 patients.
Nevertheless, our data establish a B cell–intrinsic requirement for
STK4 in humoral immunity in mice and human subjects.
We thank David Langley for help with the STK4 crystal structure. We
gratefully acknowledge the patients and families involved in the study.
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with childhood asthmaTo the Editor:
Both laboratory and epidemiologic studies have demonstrated
the importance of the gut microbiota in immunologic develop-
ment, childhood asthma, and allergic disease pathophysiology.1
Although most studies have focused on bacteria, the
methanogenic archaea that live alongside them are relatively
understudied. Archaea are prokaryotic microorganisms
belonging to their own domain of life distinct from bacteria and
Eukaryota.
Methanobrevibacter smithii and Methanosphaera stadtmanae
are the most abundant archaeal species in the gut.2 Bang et al3
and Blais-Lecours et al4 demonstrated that M stadtmanae is
particularly immunogenic in human cells and mice. Accordingly,
we hypothesized that archaea, like bacteria, might play a role in
childhood asthma or allergic disease risk, and in this letter we
present the first epidemiologic evidence linking an archaeal
species, M stadtmanae, with lower asthma risk.
We conducted cross-sectional analyses using fecal samples
available at 6 to 10 years of age for a subset of children
participating in the KOALA birth cohort study in The
TABLE I. Results for the presence of archaea (yes/no)
Exposure Outcome Sample size OR (95% CI), crude* OR (95% CI), adjusted*
M stadtmanae Asthma 472 0.38 (0.10-1.10) 0.32 (0.08-0.98)
Eczema 472 0.72 (0.34-1.46) 0.68 (0.30-1.42)
Aeroallergen sensitized 355 1.04 (0.45-2.30) 0.83 (0.32-2.02)
Food allergen sensitized 354 0.82 (0.27-2.09) 0.69 (0.21-1.95)
M smithii Asthma 472 1.17 (0.63-2.27) 1.09 (0.56-2.20)
Eczema 472 1.38 (0.86-2.25) 1.32 (0.81-2.18)
Aeroallergen sensitized 355 0.96 (0.57-1.63) 1.05 (0.59-1.89)
Food allergen sensitized 354 1.03 (0.56-1.94) 1.30 (0.68-2.59)
Boldface text indicates which results reached statistical significance, P < .05.
*The crude model is adjusted only for study design–related variables: fecal sampling round and recruitment group. The fully adjusted model also included birth mode and place,
antibiotic exposure, farm animal exposure, cat/dog exposure, body mass index z score, maternal age at delivery, maternal education, parental atopy, sibling atopy, sex, organic dairy
consumption, and abundance of the other archaeal species.
TABLE II. M stadtmanae abundance and asthma risk (sample size 5 472)
M stadtmanae
abundance No. Asthma prevalence (%) OR (95% CI), crude OR (95% CI), adjusted
Absent 433 17.3 1.00 (reference) 1.00 (reference)
Low abundance 23 13.0 0.37 (0.08-1.35) 0.43 (0.08-1.73)
High abundance 16 6.2 0.40 (0.02-2.03) 0.20 (0.01-1.18)
P value for linear association with interval-scale abundance categories .096 .036
Boldface text indicates which results reached statistical significance, P < .05.
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Repository at www.jacionline.org. The KOALA study, which is
described in detail elsewhere,5 consists primarily of children
(n 5 2359) whose mothers were recruited as healthy pregnant
women from an ongoing prospective cohort study on
pregnancy-related pelvic girdle pain. Additionally, an
‘‘alternative recruitment group’’ of 496 women was recruited
through advertisements in organic food shops, anthroposophic
doctors and midwives, Steiner schools, and dedicated magazines.
The KOALA study was approved by the Medical Ethical
Committee of the Maastricht University/University Hospital of
Maastricht and the National Ethical Committee for Medical
Research. All parents signed informed consent forms.
We requested childhood fecal samples from 1432 families,
targeting those who had already provided other biosamples, such
as maternal and child blood samples. We also oversampled for 27
asthmatic patients from within the KOALA cohort to increase
statistical power. We received 672 samples and excluded samples
with transport times of greater than 4 days, leaving 472 available
for analysis. We quantified M smithii and M stadtmanae in these
samples by using quantitative PCR and targeting regions of the
16S rRNA genes specific for these species.5
All 472 children had data on asthma and eczema diagnoses,
symptoms, and medication use from up to 4 parentally completed
questionnaires spanning 6 to 10 years of age. Three hundred
fifty-five children had total and specific serum IgE measurements
(with 1 missing for food allergens), and 337 had spirometric lung
function data. These blood samples and spirometric readingswere
taken during homevisits at 6 to 10 years of age by trained research
nurses. Serum specific IgE levels defined aeroallergen and food
allergen sensitization outcomes, and the normalized FEV1/forced
vital capacity ratio was used as a continuous lung function
outcome. Asthma diagnoses were based onmodified International
Study of Asthma and Allergies in Childhood questionnaires
requiring a reported physician’s diagnosis, as well as reportedrecent symptoms or medication use. Further details of data
collection protocols and outcome definitions are included in the
Methods section in this article’s Online Repository at
www.jacionline.org.
Asthma and eczema are overrepresented in the study
population relative to the whole KOALA cohort, as was expected
from the oversampling of asthmatic children (16.7% vs 10.4%
and 34.1% vs 28.5%, see Table E1 in this article’s Online
Repository at www.jacionline.org). A larger proportion of the
study population (24.8%) are from the alternative recruitment
group than in the overall KOALA cohort (17.4%). This was
also expected because the alternative recruits are more likely
than the conventional recruits to have early-life biosamples,
such as infant blood, because KOALA’s alternative recruitment
program began at approximately the same time as the
biosampling program. Early-life biosample availability was a
criterion for inclusion in the childhood fecal sampling program.
Further description of the study population can be found
in Table E3 in this article’s Online Repository at www.jacionline.
org.
M stadtmanae and M smithii were detectable in 8.3% and
78.2% of samples, respectively.6 Because abundance distribu-
tions of both M stadtmanae and M smithii followed an apparent
trimodal pattern (see Fig E2 in this article’s Online Repository
at www.jacionline.org), we also classified participants into 3
abundance categories.
We tested for associations between the presence of each
archaeal species and the risk of our primary outcome of asthma
using logistic regression models adjusted for multiple potential
confounders (Table I). We adjusted for recruitment group and
fecal sampling round in all analyses. No significant interaction
between recruitment group and archaeal exposure was found,
and therefore pooling these groups was considered appropriate.
Analyses involving serum IgE data were also adjusted for analytic
batch numbers.
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Seven covariates had 5 or fewer missing data, which we imputed
with the most common category or mean value. Organic dairy
consumption was imputed for 19 children by using the categories
predicted by using a regression model based on prior dietary and
lifestyle information.
Our results indicate that the presence of M stadtmanae is
associated with a lower risk of asthma at 6 to 10 years of age
(adjusted odds ratio [OR], 0.32; 95% CI, 0.08–0.98; P 5 .045;
Table I). Furthermore, the risk of asthma showed a monotonic
decrease over the 3 categories of M stadtmanae abundance
(adjusted P 5 .036 for linear trend over the M stadtmanae
abundance categories, Table II). No significant interaction was
found between M stadtmanae exposure and parental asthma
history (P 5 .495), suggesting that the association does not
significantly differ by parental asthma status.
For secondary outcomes, M stadtmanae also appeared to be
associated with a slightly lower likelihood of eczema,
aeroallergen sensitization, and food allergen sensitization, but
these associations did not reach statistical significance (Table I).
M stadtmanae was not associated with either of the continuous
outcomes of total serum IgE or FEV1/forced vital capacity z score
(see Table E4 in this article’s Online Repository at
www.jacionline.org). We found no significant associations
between M smithii and any outcome (Tables I and see
Table E4). We also conducted a complete case analysis that
produced similar results (see Table E5 in this article’s Online
Repository at www.jacionline.org).
Additionally, to check whether the oversampling of asthma
cases in the second sampling round had introduced any bias, we
repeated the analyses with only the 372 children sampled in the
first round (see Table E6 in this article’s Online Repository at
www.jacionline.org). Similar ORswere observed in this subgroup
(eg, M stadtmanae presence and asthma: OR, 0.39; 95% CI,
0.06-1.60). The lower precision observed was expected from
the smaller sample size and fewer asthma cases, and this
sensitivity analysis otherwise showed no evidence of any bias
introduced by the oversampling.
Because of the low prevalence of M stadtmanae and
cross-sectional study design, our results should be interpreted
with caution. Although bacterial species not examined in our
analysis might confound this association, we speculate that a
mechanistic link between M stadtmanae and allergic disease
appears plausible. Prior evidence demonstrates the airway and
gut immunogenicity of M stadtmanae in mouse models and
human cells.3,7 Epidemiologic evidence also indicates a
timing-dependent relationship between asthma risk and exposure
to farm environments8 whereM stadtmanae is present.9 However,
farm exposure has also been associated with risk of atopy, which
our study does not show.
Exposure to immunogenic bacterial species in infancy has been
shown to be tolerogenic and reduce asthma risk.1 Our study
identifies an association between the presence of M stadtmanae
at school age and lower asthma risk, leading us to speculate that
early-life archaeal exposures might also be tolerogenic. Therefore
we encourage further research into the immunologic roles of
archaea.
We would like to thank Christel Driessen and Erik Beuken for their
technical assistance with quantitative PCR analyses.David J. M. Barnett, MAa
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with Der p 2 prevents murine asthma
by regulating lung GM-CSFTo the Editor:
The prevalence of allergic diseases is increasing, urging new
ways of prevention. Allergen immunotherapy (AIT) is currently
the only clinical intervention that can alter the natural course of
allergy and can offer long-term clinical benefit. Although AIT is
traditionally used as a treatment in patients with established
disease, the National Institutes of Health’s Immune Tolerance
Network has proposed that prophylactic AIT could also be used as
a primary prevention for new sensitizations and allergic disease in
high-risk children born to atopic parents and with a personal
